Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
The Merck KGaA/Pfizer drug is said to have cured 52% of women with a rare gynaecological cancer, one of whom subsequently gave birth.